Enterosorb

For investing or partnering interest, please click here

Focused on restoring gut health

We are developing an innovative advanced microbiome therapeutic to address liver diseases and Irritable Bowel Syndrome (IBS).

In chronic liver disease and IBS, an imbalanced microbiome and damaged gut wall allow inflammatory molecules to leak into the bloodstream leading to serious health issues.

Potential to address significant unmet needs

Our solution, a gut-restricted oral adsorbent (YAQ001), is designed to adsorb endotoxins and interfere with the growth of harmful pathogenic bacteria without killing beneficial microbes, thus restoring the microbiome.

1GBD2017 Cirrhosis Collaborators. The global, regional and national burden of cirrhosis, The Lancet Gastroent. & Hepatology, Jan 2020
2IBS-C excludes constipation. Sperber A.D. et al. Worldwide Prevalence and Burden of Functional GI Disorders, Results of Rome Foundation Global Study, Gastroenterology, vol 160, Issue 1, Jan 2021, 99-114.e3
3Bowlus C.L. et al. AASLD practice guidance on PSC and cholangiocarcinoma. AASLD, July 2022

Our pipeline

Our Leadership

Enterosorb currently benefits from key members of Yaqrit’s leadership team. In time permanent Enterosorb appointments will be made.
Prof. Rajiv Jalan, Ph.D. Prof. Rajiv Jalan, Ph.D. Chair, Founder, CMO/CSO

Professor of Hepatology and Head of the Liver Failure Group at UCL. Key opinion leader in advanced liver disease and ACLF, extensively published

Troels Jordansen Troels Jordansen Chief Executive Officer

Over 35 years in commercial and senior leadership roles in life-sciences with an established track record in funding and growing companies

Carrie Morgan Carrie Morgan SVP Clinical Operations

More than 35 years clinical operations experience including overseeing phase 2/3 studies and securing funding in research innovation

Karen Church, Ph.D. Karen Church, Ph.D. RA, QA, Clinical Operations

Clinical and regulatory specialist. Overseen submission of 27 NDAs/MMAs/PMAs and hundreds of INDs/CTAs

Michal Kowalski, M.Eng, B.Eng Michal Kowalski, M.Eng, B.Eng SVP Operations

Experienced in scaling biotech start-ups and business engineering leveraging technical expertise and busines acument for strategic growth

Mary-Ann Chang, CFA Mary-Ann Chang, CFA SVP Communications and Strategy

Strategic communicator with more than 25 years of experience in the life-science industry, covering IR, communication and healthcare investment

Jan Bart Hak, Ph.D. Jan Bart Hak, Ph.D. Clinical, Regulatory and Quality Management

Director Medtech, Regulatory Sciences, EU, ProPharma Over 20 years of Clinical Research experience and 10 years of Regulatory and Quality Management Services for medical devices